ADRx is at the forefront of innovative drug discovery, focusing on transforming atomic structures into small molecule therapies aimed at treating neurodegenerative diseases such as Alzheimer’s, ALS, and Parkinson’s Disease. The company has pioneered the application of structure-based design to effectively disrupt protein aggregation diseases, marking a significant advancement in therapeutic development. This approach allows ADRx to identify, design, and develop therapeutics that target patient-derived pathological protein structures, which is crucial for addressing the complexities of these diseases.

The company has successfully discovered novel small molecule modulators that influence pathological protein-protein interactions, specifically targeting amyloids and biomolecular condensates. This capability not only enhances the understanding of disease mechanisms but also opens new avenues for creating effective treatments. By leveraging advanced scientific techniques, ADRx aims to provide innovative solutions that can significantly improve patient outcomes in the realm of neurodegenerative disorders.

United States

Preclinical biotechnology company leveraging proprietary structure-based technology to develop small molecule disaggregators and inhibitors targeting previously undruggable misfolded proteins in neurodegenerative diseases.  Our pipeline consists of tau, TDP-43 and alpha-synuclein programs.

ADRx

Company Details